keyword
MENU ▼
Read by QxMD icon Read
search

Palivizumab

keyword
https://www.readbyqxmd.com/read/28741863/development-of-quality-metrics-for-ambulatory-pediatric-cardiology-infection-prevention
#1
Jonathan N Johnson, Cindy S Barrett, Wayne H Franklin, Eric M Graham, Nancy J Halnon, Brandy A Hattendorf, Catherine D Krawczeski, James J McGovern, Matthew J O'Connor, Amy H Schultz, Jeffrey M Vinocur, Devyani Chowdhury, Jeffrey B Anderson
INTRODUCTION: In 2012, the American College of Cardiology's (ACC) Adult Congenital and Pediatric Cardiology Council established a program to develop quality metrics to guide ambulatory practices for pediatric cardiology. The council chose five areas on which to focus their efforts; chest pain, Kawasaki Disease, tetralogy of Fallot, transposition of the great arteries after arterial switch, and infection prevention. Here, we sought to describe the process, evaluation, and results of the Infection Prevention Committee's metric design process...
July 25, 2017: Congenital Heart Disease
https://www.readbyqxmd.com/read/28709160/effectiveness-of-palivizumab-in-high-risk-infants-and-children-a-propensity-score-weighted-regression-analysis
#2
Evan J Anderson, Phyllis Carosone-Link, Ram Yogev, Jumi Yi, Eric A F Simões
BACKGROUND: Infants with premature birth ≤35 weeks gestational age, chronic lung disease of prematurity and congenital heart disease are at an increased risk for lower respiratory tract infections and hospitalization from respiratory syncytial virus (RSV), which has been shown in randomized trials to be prevented by palivizumab. However, palivizumab effectiveness (PE) has not been studied in a large clinical setting. METHODS: A multicenter study among high-risk US and Canadian children younger than 24 months hospitalized with lower respiratory tract infection and whose nasopharyngeal aspirates were tested for human metapneumovirus (HMPV) and RSV were the subjects of the trial...
August 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28679495/dose-selection-for-an-adjuvanted-respiratory-syncytial-virus-f-protein-vaccine-for-older-adults-based-on-humoral-and-cellular-immune-responses
#3
Judith Falloon, Keipp Talbot, Craig Curtis, John Ervin, Diane Krieger, Filip Dubovsky, Therese Takas, Jing Yu, Li Yu, Stacie L Lambert, Tonya Villafana, Mark T Esser
This is the second phase 1 study of a respiratory syncytial virus (RSV) vaccine containing RSV fusion protein (sF) adjuvanted with glucopyranosyl lipid A in 2% stable emulsion (GLA-SE). In this randomized, double-blind study (NCT02289820, clinicaltrials.gov), 261 subjects aged ≥60 years received inactivated influenza vaccine (IIV) or a vaccine containing 120 μg sF with escalating doses of GLA (1, 2.5, or 5 μg) in SE or a vaccine containing 80 μg sF with 2.5 μg GLA in SE. Subjects receiving 120 μg sF with 2...
July 5, 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/28665205/recurrent-wheezing-in-childhood-and-palivizumab
#4
Heather E Hoch, Joseph M Collaco
No abstract text is available yet for this article.
July 1, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28619123/chd-and-respiratory-syncytial-virus-global-expert-exchange-recommendations
#5
Robert M R Tulloh, Constancio Medrano-Lopez, Paul A Checchia, Claudia Stapper, Naokata Sumitomo, Matthias Gorenflo, Eun Jung Bae, Antonio Juanico, Juan M Gil-Jaurena, Mei-Hwan Wu, Talal Farha, Ali Dodge-Khatami, Rocky Tsang, Gerard Notario, Colleen Wegzyn
BACKGROUND: Palivizumab is the standard immunoprophylaxis against serious disease due to respiratory syncytial virus infection. Current evidence-based prophylaxis guidelines may not address certain children with CHD within specific high-risk groups or clinical/management settings. METHODS: An international steering committee of clinicians with expertise in paediatric heart disease identified key questions concerning palivizumab administration; in collaboration with an additional international expert faculty, evidence-based recommendations were formulated using a quasi-Delphi consensus methodology...
June 16, 2017: Cardiology in the Young
https://www.readbyqxmd.com/read/28605249/product-review-on-the-monoclonal-antibody-palivizumab-for-prevention-of-respiratory-syncytial-virus-infection
#6
Bernhard Resch
Respiratory syncytial virus (RSV) accounts for about 20% of all respiratory infections in children below the age of 5 y. It is associated with up to 63% of all acute respiratory infections and up to 81% of all viral lower respiratory tract infections causing hospitalization in infants and young children. RSV leads to seasonal epidemics between November and April in the northern hemisphere. Most severe infections (RSV accounts for 50 to 80% of all cause bronchiolitis) affect infants younger than 6 months of age and high-risk infants including those born preterm with or without bronchopulmonary dysplasia and those with hemodynamically significant congenital heart disease up to an age of 24 months...
June 12, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28598593/intravenous-palivizumab-in-respiratory-syncytial-virus-infection-after-hematopoietic-stem-cell-transplant-in-children
#7
Juan Pablo Torres, Lorena I Tapia, Paula Catalán, Verónica De la Maza, Asunción Mejías
Respiratory syncytial virus (RSV) infection can cause lower respiratory tract disease and mortality in pediatric hematopoietic stem cell transplant (HSCT) recipients. We report two children who underwent HSCT and developed RSV infection simultaneously at the Bone Marrow Transplant Unit. The treatment with intravenous palivizumab was provided and sequential viral loads were measured in nasopharyngeal (NP) and whole blood samples. To our knowledge, this is the first report where RSV loads were measured in parallel (NP and blood), before and after palivizumab, in correlation with a favorable clinical outcome in both cases...
June 9, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28579233/a-phase-2-randomized-observer-blind-placebo-controlled-dose-ranging-trial-of-aluminum-adjuvanted-respiratory-syncytial-virus-f-particle-vaccine-formulations-in-healthy-women-of-childbearing-age
#8
Allison August, Gregory M Glenn, Eloi Kpamegan, Somia P Hickman, Dewal Jani, Hanxin Lu, D Nigel Thomas, Judy Wen, Pedro A Piedra, Louis F Fries
OBJECTIVE: Respiratory syncytial virus (RSV) causes significant morbidity and mortality in infants. We are developing an RSV fusion (F) protein nanoparticle vaccine for immunization of third trimester pregnant women to passively protect infants through transfer of RSV-specific maternal antibodies. The present trial was performed to assess the immunogenicity and safety of several formulations of RSV F vaccine in 1-dose or 2-dose schedules. METHODS: Placebo, or vaccine with 60μg or 120μg RSV F protein and 0...
June 27, 2017: Vaccine
https://www.readbyqxmd.com/read/28574729/respiratory-syncytial-virus-prospects-for-new-and-emerging-therapeutics
#9
Patricia A Jorquera, Ralph A Tripp
Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infections (LRTI) in infants, the elderly, and the immunocompromised. Although the development of a RSV vaccine has been a priority for >50 years, there is still no vaccine available. Treatment of RSV LRTI has remained mostly supportive, i.e. hydration and oxygenation. Palivizumab and ribavirin are the only options currently available for prevention and treatment of RSV infection, but evidence suggests that they are not fully effective...
August 2017: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/28539438/discovery-of-a-prefusion-respiratory-syncytial-virus-f-specific-monoclonal-antibody-that-provides-greater-in-vivo-protection-than-the-murine-precursor-of-palivizumab
#10
Min Zhao, Zi-Zheng Zheng, Man Chen, Kayvon Modjarrad, Wei Zhang, Lu-Ting Zhan, Jian-Li Cao, Yong-Peng Sun, Jason S McLellan, Barney S Graham, Ning-Shao Xia
Palivizumab, a humanized murine monoclonal antibody that recognizes antigenic site II on both the prefusion (pre-F) and postfusion (post-F) conformations of the respiratory syncytial virus (RSV) F glycoprotein, is the only prophylactic agent approved for use for the treatment of RSV infection. However, its relatively low neutralizing potency and high cost have limited its use to a restricted population of infants at high risk of severe disease. Previously, we isolated a high-potency neutralizing antibody, 5C4, that specifically recognizes antigenic site Ø at the apex of the pre-F protein trimer...
August 1, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28525961/passive-and-active-immunization-against-respiratory-syncytial-virus-for-the-young-and-old
#11
Tonya Villafana, Judith Falloon, M Pamela Griffin, Qing Zhu, Mark T Esser
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants worldwide and also causes significant disease in the elderly. Despite 60 years of RSV research and vaccine development, there is only one approved medicine to prevent RSV infections. Palivizumab, a monoclonal antibody (mAb) against the RSV fusion (F) protein, is indicated for preterm infants and children at high-risk for RSV infections. It is an active time in RSV vaccine and mAb development with 14 vaccines and 2 mAbs currently being tested in clinical trials as of 13 February 2017...
July 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28508992/palivizumab-prophylaxis-in-infants-with-cystic-fibrosis-does-not-delay-first-isolation-of-pseudomonas-aeruginosa-or-staphylococcus-aureus
#12
Clélia Buchs, Marie-Laure Dalphin, Stéphane Sanchez, Marie Perceval, Laurianne Coutier, Catherine Mainguy, Behrouz Kassaï-Koupaï, Philippe Reix
Respiratory syncytial virus (RSV) infections may worsen cystic fibrosis (CF) lung disease and favor Pseudomonas aeruginosa (Pa) or Staphylococcus aureus (Sa) acquisition, which is of particular importance in the youngest patients. We aimed to determine the effectiveness of PVZ on microbiological outcomes in young children with CF. We conducted a retrospective case-control study to compare these outcomes in children who systematically received PVZ (PVZ+; n = 40) or not (PVZ-; n = 140). One case was matched with at least three same-gender controls born the same year and month...
May 16, 2017: European Journal of Pediatrics
https://www.readbyqxmd.com/read/28500974/ongoing-developments-in-rsv-prophylaxis-a-clinician-s-analysis
#13
REVIEW
Fariba Rezaee, Debra T Linfield, Terri J Harford, Giovanni Piedimonte
Respiratory syncytial virus (RSV) is the most common respiratory pathogen in infants and young children worldwide. Lower respiratory tract infection due to RSV is one of the most common causes of hospitalization for infants, especially those born premature or with chronic lung or heart disease. Furthermore, RSV infection is an important cause of morbidity in adults, particularly in the elderly and immunocompromised individuals. The acute phase of this infection is often followed by episodes of wheezing that recur for months or years and usually lead to a physician diagnosis of asthma...
May 10, 2017: Current Opinion in Virology
https://www.readbyqxmd.com/read/28469033/a-highly-potent-extended-half-life-antibody-as-a-potential-rsv-vaccine-surrogate-for-all-infants
#14
Qing Zhu, Jason S McLellan, Nicole L Kallewaard, Nancy D Ulbrandt, Susan Palaszynski, Jing Zhang, Brian Moldt, Anis Khan, Catherine Svabek, Josephine M McAuliffe, Daniel Wrapp, Nita K Patel, Kimberly E Cook, Bettina W M Richter, Patricia C Ryan, Andy Q Yuan, JoAnn A Suzich
Prevention of respiratory syncytial virus (RSV) illness in all infants is a major public health priority. However, no vaccine is currently available to protect this vulnerable population. Palivizumab, the only approved agent for RSV prophylaxis, is limited to high-risk infants, and the cost associated with the requirement for dosing throughout the RSV season makes its use impractical for all infants. We describe the development of a monoclonal antibody as potential RSV prophylaxis for all infants with a single intramuscular dose...
May 3, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28467807/the-antigen-binding-fragment-of-human-gamma-immunoglobulin-prevents-amyloid-%C3%AE-peptide-folding-into-%C3%AE-sheet-to-form-oligomers
#15
Victòria Valls-Comamala, Biuse Guivernau, Jaume Bonet, Marta Puig, Alex Perálvarez-Marín, Ernest Palomer, Xavier Fernàndez-Busquets, Xavier Altafaj, Marta Tajes, Albert Puig-Pijoan, Rubén Vicente, Baldomero Oliva, Francisco J Muñoz
The amyloid beta-peptide (Aβ) plays a leading role in Alzheimer's disease (AD) physiopathology. Even though monomeric forms of Aβ are harmless to cells, Aβ can aggregate into β-sheet oligomers and fibrils, which are both neurotoxic. Therefore, one of the main therapeutic approaches to cure or delay AD onset and progression is targeting Aβ aggregation. In the present study, we show that a pool of human gamma immunoglobulins (IgG) protected cortical neurons from the challenge with Aβ oligomers, as assayed by MTT reduction, caspase-3 activation and cytoskeleton integrity...
June 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/28444095/judicial-demand-of-medications-through-the-federal-justice-of-the-state-of-paran%C3%A3
#16
Renato Mitsunori Nisihara, Ana Carolina Possebom, Luiza de Martino Cruvinel Borges, Ana Claudia Athanasio Shwetz, Fernanda Francis Benevides Bettes
Objective: To describe the profile of lawsuits related to drug requests filled at the Federal Justice of the State of Paraná. Methods: A cross-sectional study, and the data were obtained through consulting the lawsuits at the online system of the Federal Justice of Paraná. Results: Out of 347 lawsuits included in the study, 55% of plaintiffs were women, with a median age of 56 years. Oncology was the field with more requests (23.6%), and the highest mean costs...
January 2017: Einstein
https://www.readbyqxmd.com/read/28443266/cost-effectiveness-of-palivizumab-compared-to-no-prophylaxis-in-term-infants-residing-in-the-canadian-arctic
#17
Anna Banerji, Kaspar Ng, Theo J Moraes, Vladimir Panzov, Joan Robinson, Bonita E Lee
BACKGROUND: Hospital admissions for respiratory syncytial virus infection result in large health expenditures for Inuit infants. Palivizumab has been shown to be highly effective in reducing such admissions in preterm Inuit infants. We performed a cost-effectiveness analysis estimating the incremental cost-effectiveness ratio (ICER) for palivizumab prophylaxis per admission related to respiratory syncytial virus avoided in healthy term infants across the Canadian Arctic. METHODS: We compared universal palivizumab prophylaxis in term infants less than 6 months of age to no prophylaxis in 8 Arctic regions: the Northwest Territories, Nunavut, Nunavut without Iqaluit, the 3 subregions of Nunavut (Kitikmeot, Kivalliq and Qikiqtaaluk), the Qikiqtaaluk Region without Iqaluit, and Nunavik (northern Quebec)...
October 2016: CMAJ Open
https://www.readbyqxmd.com/read/28437470/respiratory-syncytial-virus-neutralizing-serum-antibody-titers-in-infants-following-palivizumab-prophylaxis-with-an-abbreviated-dosing-regimen
#18
Jennifer Claydon, Amitava Sur, Allison Callejas, Mihoko Ladd, Eddie Kwan, Richard Taylor, Stuart E Turvey, Alfonso Solimano, Pascal M Lavoie, Nico Marr
BACKGROUND: Monthly injections of palivizumab during the respiratory syncytial virus (RSV) season in at-risk infants reduces RSV-associated hospitalizations. However, the additive effect of naturally acquired immunity remains unclear. The objective of this study was to assess total neutralizing serum antibodies (NAb) against RSV in at-risk infants who had received an abbreviated course of palivizumab prophylaxis. METHODS: Serum samples were collected from infants enrolled in the RSV Immunoprophylaxis Program in British Columbia, Canada over 2 consecutive RSV seasons (2013 to 2015)...
2017: PloS One
https://www.readbyqxmd.com/read/28437435/infective-respiratory-syncytial-virus-is-present-in-human-cord-blood-samples-and-most-prevalent-during-winter-months
#19
Angela Mary Fonceca, Abha Chopra, Avram Levy, Paul Stanton Noakes, Matthew Wee-Peng Poh, Natasha Leanne Bear, Susan Prescott, Mark Lloyd Everard
BACKGROUND: Human respiratory syncytial virus (RSV) remains the most common cause of severe lower respiratory tract disease amongst infants, and continues to cause annual epidemics of respiratory disease every winter worldwide. Demonstrating placental transmission of viable RSV in human samples is a major paradigm shift in respiratory routes considered likely for RSV transmission. METHODS: Droplet digital PCR (ddPCR) was used to identify RSV present in cord blood mononucleocytes (CBM)...
2017: PloS One
https://www.readbyqxmd.com/read/28425254/wheezing-asthma-and-atopy-in-premature-infants-at-2-years-of-age
#20
Sevim Ünal, Ayşenur Kaya, Leyla Bilgin, Emine Misirlioğlu, Can Naci Kocabaş
BACKGROUND/AIM: We aimed to evaluate wheezing, bronchial asthma (BA), and atopy in premature infants at 2 years of age via a cross-sectional study. MATERIALS AND METHODS: Premature infants at <37 weeks of gestational age (GA) were assessed for atopy by skin-prick test and serum immunoglobulin E level at 2 years of age. The family's and infant's histories of allergy, BA, atopy, and wheezing were obtained by questionnaire and from hospital records. RESULTS: There were 98 infants, with mean birth weight (BW) 1517...
April 18, 2017: Turkish Journal of Medical Sciences
keyword
keyword
44503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"